Nicardipine vs Esmolol Craniotomy Emergence

Completed · Phase 1

Conditions studied: Brain Tumors

In brief

Emergence hypertension is a common occurrence in patients emerging from general anesthesia. This elevation of arterial pressure is particularly concerning in patients undergoing craniotomy due to increased risk of morbidity and mortality in patients with altered intracranial elastance. Thus, identifying better methods to attenuate the hemodynamic changes associated with emergence from anesthesia can improve patient safety, especially in the neurosurgical patient. Study Hypothesis: Nicardipine is more effective than esmolol as a sole agent in maintaining blood pressure within goal range in the setting of emergence hypertension after craniotomy.

Key facts

Study ID

NCT01951950

Run by

Northwestern University

People needed

40

Starts

2013-09-01

Expected to finish

2014-05-01

Last updated by the study team

2014-08-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult
• non-pregnant patients
• (age ≥ 18 years)
• undergoing general anesthesia for elective supratentorial, infratentorial, or transsphenoidal craniotomy

You may not qualify if…

• Patients under 18 years of age
• non-English speaking, pregnancy
• emergent craniotomy (including trauma)
• awake craniotomy
• active 3 vessel coronary artery disease or left main coronary artery disease
• advanced heart block
• severe aortic stenosis
• chronic renal failure
• known or suspected allergy or intolerance to a study drug or its components

Where it is running

• Northwestern Memorial Hospital — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.